

Flow chart for intervention (biomarker / diagnostic) arm of *BioDriveAFS* trial

Intervention (biomarker / diagnostic) patient

- **No** antifungal prophylaxis should be prescribed for these patients. Perform baseline galactomannan (GM) and beta-D-glucan (BG) blood tests at study entry and before each new cycle of chemotherapy
 - **Test cut-offs:** All GM cut-offs refer to Platelia assay. Except where stated, serum GM ≥ 0.5 = POSITIVE. For all other GM and BG assays, POSITIVE = above the upper limit of normal (as used locally)
 - Commence twice weekly GM and BG testing just before or at onset of neutropenia and continue until at least 7 days after neutrophil count recovery (defined by usual local practice) with each chemotherapy cycle
 - When patient is being managed as an outpatient, GM and BG to be done at routine clinic visits (to a maximum of twice weekly; no extra visits required)
- IMPORTANT NOTE 1:** Clinical team can override this flow chart at any time – if flow chart is not followed, it is important reasons for this are documented in the case report form (CRF)
- IMPORTANT NOTE 2:** If local clinical and/or research team feel an adverse event has occurred as a result of this flow chart (e.g. a false positive or negative test), an adverse or serious adverse event CRF should be completed
- Many thanks for your support with this important clinical trial**

